Showing results (421-430 of 436) with videos related to
Sort By:
Pageof 44
Cancer Cell|May 19, 2023
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)Yunpeng Yang, Jianji Pan, Hui Wang, et al.Signal Transduction and Targeted Therapy|June 8, 2026
Efficacy and safety of toripalimab in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): a phase 1b/2 studyYe Guo, Zhendong Li, Liqiong Xue, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 22, 2025
INDUCE-3: A randomized Phase II/III study of first-line feladilimab plus pembrolizumab in patients with recurrent/metastatic head and neck squamous cell carcinomaDanny Rischin, Aaron R Hansen, Ezra E W Cohen, et al.Cancer Research Communications|March 6, 2023
A Phenogenetic Axis that Modulates Clinical Manifestation and Predicts Treatment Outcome in Primary Myeloid NeoplasmsQiujin Shen, Yahui Feng, Xiaowen Gong, et al.Lancet (London, England)|October 22, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in ChinaYunpeng Yang, Huaqiang Zhou, Linquan Tang, et al.Journal of Hematology & Oncology|January 13, 2021
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)Yuankai Shi, Jianqiu Wu, Zhen Wang, et al.Journal of Visualized Experiments : Jove|March 26, 2019
Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert ConsensusJing Liu, Roberto Copetti, Erich Sorantin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2026
Amivantamab in recurrent/metastatic HNSCC after checkpoint inhibitor and chemotherapy: pivotal results from the phase 1b/2 OrigAMI-4 studyBarbara Burtness, Ari J Rosenberg, Benoit Calderon, et al.Nature Communications|September 25, 2025
Autonomous artificial intelligence prescribing a drug to prevent severe acute graft-versus-host disease in HLA-haploidentical transplantsJunren Chen, Yigeng Cao, Yahui Feng, et al.Translational Lung Cancer Research|December 13, 2023
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced <i>EGFR</i>-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort studyDongming Zhang, Xiaoyan Liu, Fangfang Shen, et al.Pageof 44